Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the drug Mobocertinib will be available on the NHS.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations on whether drugs represent a clinically and cost-effective use of National Health Service resources. The NHS in England is legally required to fund all medicines NICE recommends, usually within three months of final guidance, and cancer drugs are eligible for funding through the Cancer Drugs Fund (CDF) immediately after NICE issues positive draft guidance.

NICE published final draft guidance recommending mobocertinib for the treatment of locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor exon 20 insertion mutations on 16 November 2022. It is therefore routinely available for clinicians to prescribe to eligible NHS patients in line with NICE’s recommendations, having been previously funded through the CDF.